Bruker Expands Collaboration with Noetik to Advance Tissue Foundational Models for Translational and Therapeutic Applications

Key Terms

spatial molecular imager technical

A spatial molecular imager is a laboratory instrument that maps the precise locations of biomolecules — such as RNA and proteins — within tissue slices or cell samples, producing images that show which molecules appear where. It matters to investors because those spatial maps make complex biology visual and actionable, speeding drug discovery, biomarker validation and diagnostic development; companies selling the instruments, software, or analysis services can generate recurring revenue from research labs, hospitals and biotech firms.

spatial transcriptomic medical

Spatial transcriptomic is a laboratory method that measures which genes are active inside a tissue while keeping track of their exact locations, producing a map of gene activity across a sample. For investors, it matters because those location-aware maps help researchers spot disease patterns, identify drug targets and improve diagnostics—like turning a flat list of symptoms into a city map that shows precisely where problems cluster, which can speed and de-risk development of treatments and tests.

multiomic medical

Multiomic describes the combined analysis of different layers of biological information—such as genes, proteins and small molecules—to build a more complete picture of how cells and diseases work. Like viewing a problem from several camera angles instead of one, it can reveal stronger drug targets, clearer diagnostic markers and better predictions of who will benefit from a therapy, which helps investors assess scientific validity, market potential and development risk.

whole transcriptome assay medical

A whole transcriptome assay is a laboratory test that measures all the RNA messages produced by cells, giving a complete snapshot of which genes are active and how much they are expressing. Like eavesdropping on every conversation in a city to understand what people are doing, it helps researchers find disease markers, drug targets, and patient groups, which can materially affect a biotech company’s development prospects and commercial value.

single-cell medical

Single-cell describes laboratory methods and data that examine individual cells instead of averaging signals from many cells together. Like listening to each instrument in an orchestra instead of the whole band at once, single-cell approaches reveal rare cell types, differing behaviors, and precise molecular signals that can identify disease drivers, predict who will respond to a therapy, or enable targeted diagnostics—insights that can create new product opportunities and competitive advantages for biotech and healthcare investors.

subcellular medical

Subcellular describes structures or processes that occur inside a cell, at the level of organelles, molecules, or compartments smaller than the whole cell. For investors, the term flags that a drug, diagnostic or technology acts on very specific internal parts of cells—like fixing a single room in a house rather than renovating the whole building—which can imply greater precision, different risks, and specific development or manufacturing challenges.

translational research medical

Translational research turns laboratory discoveries into tests, treatments, or medical products for people, acting as the bridge between basic science and practical use. Like converting a prototype into a store-ready product, it shows whether promising biology can become a safe, regulated, and sellable therapy, diagnostic, or device. For investors, clear translational progress reduces technical and regulatory uncertainty, creates milestone-driven value, and signals when commercial returns might be possible.

foundation models technical

Foundation models are very large artificial intelligence systems trained on broad, general data so they can be quickly adapted to many different tasks, like a powerful, general-purpose engine or a Swiss Army knife for software. They matter to investors because they can lower costs and speed innovation across industries, create new products or revenue streams, and change competitive dynamics, while also introducing operational and regulatory risks that can affect a company’s financial outlook.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ORLANDO, Fla.--(BUSINESS WIRE)-- Bruker Spatial Biology, a division of Bruker Corporation (Nasdaq: BRKR) announced today that it will expand its collaboration with Noetik Inc., following their prior study of more than 3500 patient samples with the CosMx^® Spatial Molecular Imager (SMI). CosMx SMI powers Noetik's pre-training and scaling of bio-foundation models to perform complex genome-wide simulations of human cellular- and tissue-level biology to enable diverse therapeutics applications.

“Noetik’s multiple spatial AI models, including the Oncology Counterfactual Therapeutics Oracle virtual cell, which can simulate patient biology and inform drug discovery, represent transformative breakthroughs for tackling human disease,” said Dr. Mark R. Munch, President of the Bruker NANO Group. To develop self-supervised AI, Noetik leverages the CosMx SMI platform to generate the largest and most biologically complete single-cell and subcellular spatial transcriptomic and multiomic datasets in oncology.

Noetik is now further imaging thousands of additional patients with the CosMx whole transcriptome assay to train their world models that learn from human tissue data.

“Spatial context is necessary for training foundation models that truly learn human biology. We have demonstrated that our models exhibit clear scaling laws; as we ingest more high-resolution CosMx data, we see a predictable and powerful increase in the models' ability to represent complex biology. We are excited to partner with Bruker to scale toward one billion spatially resolved human cells, spanning the breadth of oncology and beyond,” said Ron Alfa, MD, PhD, Co-Founder and CEO of Noetik.

This collaboration builds on Bruker’s best-in-class spatial biology portfolio, including CosMx SMI, AtoMx^® SIP, CellScape™ XR, GeoMx^® DSP and PaintScape™ platform, which together support high fidelity data generation for discovery and translational research.

Join Bruker at AGBT 2026

Bruker will share more details on recent advancements to CosMx SMI, alongside innovations across the entire Bruker Spatial Biology portfolio, at the AGBT hospitality suite in Dade Lounge throughout the week and in their Silver Sponsor Workshop on Wednesday, February 25.

For more information, please visit www.brukerspatialbiology.com.

About Bruker Corporation – Leader of the Post-Genomic Era

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

About Noetik

NOETIK is a frontier therapeutics company harnessing AI to deeply understand human biology and redefine clinical outcomes in oncology. Leveraging the largest proprietary multimodal oncology dataset of its kind, uniquely integrating spatial biology, NOETIK’s OCTO series of models (Oncology Counterfactual Therapeutics Oracle) precisely match therapeutic targets to patient subpopulations and accurately predict clinical efficacy. This AI-first approach elevates therapeutic development from probabilistic guesswork to precision science. By strategically partnering with clinical developers and in-licensing promising therapeutics, NOETIK accelerates the delivery of transformative cancer treatments to patients. To learn more about Noetik, visit https://www.noetik.ai.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260224789530/en/

Bruker Investor Contact:
Joe Kostka
Director, Investor Relations
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

Bruker Media Contact:
Johnny Lyssand, PhD
Senior Director, Downstream Marketing
Bruker Spatial Biology
T: +1 (206) 790-2843
E: john.lyssand@bruker.com

Noetik Media Contact:
Thermal for Noetik
noetik@thermalpr.com

Source: Bruker Corporation